Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4HQ1F
|
|||
| Drug Name |
Zolbetuximab
|
|||
| Synonyms |
IMAB362
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Esophagogastric junction neoplasm [ICD-11: 2B71] | Phase 3 | [1] | |
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 3 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 2 | [2] | ||
| Company |
Astellas Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-18 (CLDN18) | Target Info | . | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Tight junction | ||||
| Leukocyte transendothelial migration | ||||
| Hepatitis C | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Tight junction interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03816163) A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health. | |||
| REF 3 | FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.